Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for ...
Arctic Therapeutics (ATx) today announced that the first patients have been enrolled in a Phase IIa randomized, ...
Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...
Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and ...
Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...
Poolbeg Pharma plc - Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology 28 January 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage ...
Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.
"The consistency of treatment effect across disease locations is important, as ileal Crohn's disease (CD) is highly correlated with negative long-term outcomes and the fact that the terminal ileum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results